Moderna is cutting its R&D spend, but it needs products to return to growth
Moderna, one of the most visible pharmaceutical brands of the pandemic, is struggling to adapt to a post-COVID world. Shares in the company were trading down as much as 18% earlier today after announc...
Eli Lilly's Zepbound rises while Novo Nordisk's Ozempic levels off
Eli Lilly may eventually catch up to Ozempic maker Novo Nordisk when it comes to selling the weight loss drugs that have boomed in popularity in recent years. Eli Lilly reported on Thursday that sales...
Doses delivered: Drugmaker Eli Lilly wants to sell to you directly
Gilded Lilly Yesterday, pharma giant Eli Lilly announced the launch of ‘LillyDirect’ , a direct-to-consumer telehealth service designed to simplify medicine deliveries for users, particularly for pop...
Smaller doses: Pfizer's finances aren't what they were
Long shot It seems like just yesterday that pharmaceutical company Pfizer, which pioneered one of the first vaccines for the COVID-19 virus, was being lauded as an American hero of the pandemic. Howe...
Covid catchup: The latest data as hospitalizations rise
New formula The FDA has approved an updated batch of Covid boosters from pharmaceutical companies Moderna and Pfizer as the agency continues to monitor rising Covid hospitalizations across the US . ...
New ground for Novo: Denmark's largest company just keeps getting bigger
Outweighed Novo Nordisk, the Danish pharma company responsible for Ozempic and Wegovy — two of the buzziest drugs in the weight loss game — has been bulking up, with its market cap. recently crossin...
Trending: Will weight loss drugs be another fading fad?
Tightening belts When set against that not-insignificant backdrop, it’s perhaps too soon to say whether weight loss drugs — or diabetes drugs that make you lose weight — could provide a lasting answe...
Weighting game: America's obesity rate is much higher than 6 decades ago
Weighting game While there’s nothing particularly new about people trying to manage and keep their weight down, the number of people who may be tempted to experiment with medical remedies like Ozempi...
Scaling up: Ozempic's become the most in-demand diabetes drug in the US
In 2012, Danish pharmaceutical giant Novo Nordisk developed semaglutide, a medication to be taken once a week to help tackle type 2 diabetes. The injectable drug was trialed in 2016 and was approved b...
Pfizer: The pharma giant is putting its Covid cash to work
Pfizer’s dealmaking continues to accelerate, as the company is reportedly in talks to acquire Seagen, a biotech company with a number of promising cancer treatments, in a deal that could be worth more...
Nobel efforts: Sequencing human genomes is getting cheaper
Nobel efforts Svante Pääbo, a Swedish scientist, has won the Nobel Prize for his reconstruction of a full genome for Neanderthals and other extinct hominins. Pääbo's prize, officially the Nobel Priz...
Drugs are expensive: Americans pay a lot for pharmaceuticals
This week a new study from Harvard Medical School researchers estimated that Medicare could save almost $4bn a year were it to purchase drugs and prescriptions from Mark Cuban's Cost Plus Drug Company...
Pfizer's big year
It's likely that a good proportion of you reading this newsletter received a Pfizer-BioNTech COVID-19 vaccine at some point in the last 18 months. For Pfizer, those billions of doses have translated i...
OpenAI grows healthcare offerings with an AI assistant for cancer patients
OpenAI is making more moves in the healthcare space — an industry considered by many to be prime for AI innovation. Color Health has developed a promising use case: an AI assistant that uses OpenAI’s ...
Ozempic and other GLP-1s are booming, so why are businesses talking about them less?
GLP-1 agonists, a type of medication used to treat obesity, are big business and only growing. All things considered, Goldman Sachs expects the market size to grow from about $10 billion now to around...
Did South Park mark the top for weight-loss stocks?
South Park doesn’t just kill Kenny. It may also kill stock market trends. In the May 24 television special “End of Obesity,” writer Trey Parker directly name-checks Ozempic , the weight-loss drug made...
Ozempic and Wegovy are driving Novo Nordisk’s sales higher
Novo Nordisk, the pharma giant that’s become even more giant thanks to its weight loss drugs Ozempic and Wegovy, reported first-quarter earnings yesterday. Although the company technically raised its ...
Ozempic, Wegovy drive Novo Nordisk profits up
Shares of Danish drugmaker Novo Nordisk fell on Thursday, as investors digested the latest hard numbers from the maker of heavily-hyped drugs Ozempic and Wegovy. For the record, sales of both continu...
Novo Nordisk’s market cap is bigger than Denmark’s entire economy
Something is shapely in the state of Denmark. Thanks to the success of its diabetes and obesity drugs Ozempic and Wegovy, drugmaker Novo Nordisk is now Europe’s most valuable company. It’s especially ...